Nurix Therapeutics, Inc. (NRIX): Total Liabilities
$149.39M
As of 2025-11-30
$132.91M
As of 2026-05-31
+9.7%
3-year compound annual growth
+7.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $149.39M | +4.9% | 2026-01-28, Balance as of period end |
| 2024-11-30 | $142.35M | -8.2% | 2026-01-28, Balance as of period end |
| 2023-11-30 | $155.10M | +37.2% | 2025-01-28, Balance as of period end |
| 2022-11-30 | $113.06M | -15.9% | 2024-02-15, Balance as of period end |
| 2021-11-30 | $134.47M | +26.8% | 2023-02-09, Balance as of period end |
| 2020-11-30 | $106.07M | +98.0% | 2022-01-28, Balance as of period end |
| 2019-11-30 | $53.57M | n/a | 2021-02-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $149.39M | +4.9% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $213.39M | +126.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $508.98M | -3.0% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $2.08B | +35.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗